MSGERC Grand Rounds Webinar Series

Grand Rounds Webinar Series, Episode 2: Cryptococcosis – Updated Management Strategies (Archived Version)

Check out the archive of the second MSGERC Grand Rounds Webinar. In this episode, Drs John Baddley and Jeremey Walker, with guest Dr David Boulware, discuss updated management strategies in cryptococcosis, with a particular focus on the new data from the AMBITION trial as well as the putative COVID-19 and cryptococcosis connection. Using a case-based approach, they explore topics such as risk factor assessment and optimal therapeutics. The webinar also features commentary from John Perfect, MD.

Cryptococcosis: Updated Management Strategies
Recorded May 27, 2022.

John W. Baddley, MD, MSPH

Professor of Medicine
Institute of Human Virology
University of Maryland Stewart and Marlene Greenebaum Cancer Center
Baltimore, Maryland

Dr John W. Baddley is a Professor of Medicine at the Institute of Human Virology and the University of Maryland Stewart and Marlene Greenebaum Cancer Center. He previously taught at the University of Alabama at Birmingham (UAB), where he was Professor of Medicine in the Division of Infectious Diseases. After receiving an undergraduate degree from the University of North Carolina at Chapel Hill, Dr Baddley earned his medical degree from Louisiana State University (LSU) School of Medicine, New Orleans. He completed an internship and residency at LSU Medical Center and a fellowship in infectious diseases at University of Alabama at Birmingham, where he was Chief Infectious Diseases Fellow. At UAB he served as Director, Transplant Infectious Diseases, in its Comprehensive Transplant Institute and Director of the Infection Control Program at the Birmingham VA Medical Center. His clinical work focuses on prevention and management of infections in the immunocompromised host. He also participates in outpatient clinic and inpatient consult services for solid organ transplant and cancer patients. In addition, Dr Baddley holds a part-time position at the Baltimore (MD) VA Hospital, where he is involved with antimicrobial stewardship and clinical work in the Infectious Diseases clinic.

Dr Baddley’s research interests include clinical trials and outcomes research related to immunocompromised hosts, focusing on novel antifungal and cytomegalovirus therapies, epidemiology of fungal infections, HIV transplantation, and risk of infection and outcomes with the use of biological therapies/immunomodulators. Dr Baddley currently serves as an Associate Editor of Open Forum Infectious Diseases and is on the American Board of Internal Medicine’s Infectious Disease Exam Committee. He also is co-chair of the education committee of the Mycoses Study Group Education and Research Consortium and the Secretary/Treasurer of the Transplant Infectious Diseases group of the Transplantation Society. He recently served as Chair of the World Health Organization’s Histoplasmosis Guidelines Development Group.

Jeremey Walker, MD

Associate Scientist
Center for Clinical and Translational Science
General Clinical Research Center
Assistant Professor, Medicine
Infectious Diseases, Department of Medicine
University of Alabama Medical Center
Birmingham, Alabama

Jeremey Walker, MD, is Assistant Professor of Medicine and Infectious Diseases in the department of Medicine at the University of Alabama Medical Center. Dr Walker specializes in treatment and prevention of infection in Immune-compromised hosts including solid organ transplant and malignancy. This includes working as an associate healthcare epidemiologist with focus on areas serving this population. Dr Walker earned his Doctor of Medicine, Internship, Residency, and Fellowship at University of Alabama School of Medicine. Dr Walker has published on a range of infectious diseases topics, including the role of fecal microbiota in management of C difficile infection as well as COVID-19 prevention. Most recently, Dr Walker has led an effort to characterize the connection between COVID-19 and cryptococcal infection, particularly in solid organ transplant patients.

This educational initiative was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC-RFA-CK20-2003) to the University of Alabama at Birmingham. The University of Alabama at Birmingham is collaborating with the Mycoses Study Group Education & Research Consortium and Terranova Medica, LLC, on this initiative. The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource center do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement by the Federal Government.